GLP-3 in Alpharetta: What It Actually Is

What GLP-3 actually is

GLP-3 is a nickname, not a hormone. It is the label that has attached itself online to a new class of triple-agonist weight-loss compounds, and when people search for GLP-3 they are almost always looking for retatrutide — Eli Lilly compound code LY3437943, currently in phase 3 trials.

The distinction matters, and it is the one thing most GLP-3 pages get wrong. GLP-1 and GIP are real hormones with real receptors. There is no GLP-3 hormone and no GLP-3 receptor. So while GLP-3 is a perfectly serviceable nickname for the drug, nothing in your body is a GLP-3 receptor waiting to be activated. What the compound actually does is activate three separate receptors that do exist: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCG) receptor.

If a website tells you GLP-3 is the next hormone after GLP-1 and GLP-2, that site does not know what it is describing. The honest version is more interesting anyway.

How GLP-3 works

The reason GLP-3 generated so much attention is the third receptor. GLP-1 drugs such as semaglutide hit one target. Tirzepatide hits two. The compound behind the GLP-3 nickname hits three, and the third one is glucagon.

That combination is designed to stack three different metabolic effects. GLP-1 and GIP receptor activity is associated with appetite reduction and improved insulin secretion — the mechanism people already recognize from current weight-loss drugs. Glucagon receptor activity is associated with increased energy expenditure, which is a different lever entirely. In plain terms, the first two receptors are thought to reduce how much you want to eat, and the third is thought to increase how much you burn.

Glucagon is usually discussed in terms of raising blood glucose, so including it may look counterproductive. The rationale is that in combination with GLP-1 and GIP activity, the net effect is theorized to support weight reduction beyond appetite suppression alone. This remains a mechanism under active investigation, not a settled fact about long-term performance across a broad population.

What the GLP-3 research actually shows

The substantial published evidence is a phase 2, randomized, double-blind, placebo-controlled trial of 338 adults with obesity, or overweight plus at least one weight-related condition, run at US sites from May 2021 through November 2022. Participants received once-weekly subcutaneous injections across several dose groups or placebo for 48 weeks, with lifestyle counseling in every arm. In the highest-dose group at 12 mg, the least-squares mean body-weight reduction at 48 weeks was 24.2% (Jastreboff et al., 2023, Triple–Hormone-Receptor Agonist Retatrutide for Obesity, New England Journal of Medicine).

That 24.2% number is the one driving most of the GLP-3 conversation online, so it is worth stating precisely what stands behind it. It is a phase 2 result. The 12 mg arm that produced it was 62 people. None of the 338 participants had type 2 diabetes. Every arm including placebo received lifestyle counseling. It is a genuinely striking figure and a legitimate reason for interest — and it is one dose group in one mid-stage trial, not a population-wide expectation.

Development has since advanced into phase 3, where Eli Lilly has reported topline results from its TRIUMPH program (Lilly investor announcement, TRIUMPH phase 3 program). Phase 3 progress is not FDA approval, and full peer-reviewed phase 3 publications deserve to be read on their own terms as they appear.

What GLP-3 is not

It is not FDA approved, for any indication. It should not be described as approved, as available by prescription in the ordinary sense, or as ready for routine clinical use.

It is not legally compoundable. The FDA has confirmed that compounding retatrutide is prohibited under both sections 503A and 503B of the FD&C Act, because it does not appear on the permitted bulks lists and is not a component of an approved drug product. The agency has separately warned consumers about unapproved products sold online containing it (FDA letter on retatrutide in compounded drug products). If a clinic or website offers to sell you compounded GLP-3, that is a signal to walk away — from the product and from the vendor.

And it is not a personal weight-loss guarantee. A mean reduction in a trial population describes what happened in that study. It is not a promise to any individual.

How Aeon approaches GLP-3

Because it is investigational, not FDA approved, and not legally compoundable, Aeon Wellness Club does not offer GLP-3. We do get asked about it constantly, and we would rather give you the accurate version than the marketing version.

If you are researching GLP-3 because you want serious help with weight, that goal is very much addressable today with approved therapies. Our medical weight loss program pairs licensed provider oversight with measured resting metabolic rate, comprehensive lab work, body composition tracking, and resistance training built to protect lean mass — the part most weight-loss efforts sacrifice by accident.

A real compound with a genuine three-receptor mechanism, real phase 2 results in a leading journal, and a regulatory status that currently rules out both prescribing and compounding. That is a more useful story than "GLP-3, proven, available now," and it is the one that will still be true next year.